Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 17;102(2):294-320.
doi: 10.1016/j.neuron.2019.03.014.

Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions

Julia K Nussbacher  1 , Ricardos Tabet  2 , Gene W Yeo  3 , Clotilde Lagier-Tourenne  4
Affiliations
Review

Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions

Julia K Nussbacher et al. Neuron. .

Abstract

RNA binding proteins are critical to the maintenance of the transcriptome via controlled regulation of RNA processing and transport. Alterations of these proteins impact multiple steps of the RNA life cycle resulting in various molecular phenotypes such as aberrant RNA splicing, transport, and stability. Disruption of RNA binding proteins and widespread RNA processing defects are increasingly recognized as critical determinants of neurological diseases. Here, we describe distinct mechanisms by which the homeostasis of RNA binding proteins is compromised in neurological disorders through their reduced expression level, increased propensity to aggregate or sequestration by abnormal RNAs. These mechanisms all converge toward altered neuronal function highlighting the susceptibility of neurons to deleterious changes in RNA expression and the central role of RNA binding proteins in preserving neuronal integrity. Emerging therapeutic approaches to mitigate or reverse alterations of RNA binding proteins in neurological diseases are discussed.

Keywords: ALS; FMRP; RNA binding protein; Repeat expansion; SMA; SMN; TDP-43; autism; dementia; hnRNP.

PubMed Disclaimer

Conflict of interest statement

DECLARATION OF INTERESTS

G.W.Y. is co-founder, member of the Board of Directors, equity holder, and paid consultant for Locana and Eclipse BioInnovations. G.W.Y. is co-founder of Enzerna and ProteoNA. G.W.Y. is a paid consultant for Aquinnah Pharmaceuticals and Ionis Pharmaceuticals and scientific advisory board member to Ribometrix and the Allen Institute of Immunology. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. The authors declare no other competing financial interests.

Figures

Figure 1.
Figure 1.. Mechanisms Leading to Disruption of RBPs in Neurodegenerative Diseases
(A) Expression of RBPs may be reduced by point mutations, abnormal splicing, aberrant repeat expansions that repress the RBP transcription, and neutralization by autoantibodies in paraneoplastic neurological syndromes. (B) Abnormal phase transition of RBPs with low complexity domains leads to their aggregation and mislocalization with loss of function and/or gain of novel toxic properties. (C) Expanded repeats in microsatellite diseases may lead to sequestration of RBPs into RNA foci and/or abnormal interaction with repeat-containing proteins translated from the expansion. (D) Disruption of RBPs has a widespread effect on the metabolism of their RNA targets including abnormal splicing, polyadenylation, transport, translation, and decay with downstream effects on cellular morphology and function.
Figure 2.
Figure 2.. Therapeutic Strategies to Restore the Level and Function of RBPs in Neurodegenerative Diseases
(A) Strategies to restore RBP expression level. (i) Antisense oligonucleotides (ASOs) enhance inclusion of SMN2 exon 7 resulting in increased levels of SMN2 protein. (ii) Exon 7 inclusion in SMN2 achieved via small-molecule recruiting U1 snRNP. (iii) Restoration of SMN2 proteins levels through inhibition of Histone deacetylases (HDACs). (iv) Restoration of SMN1 protein level by AAV-mediated genetherapy. (v) Promotion of FMR1 expression using deactivated Cas9 (dCas9) fused to Tet1 that when targeted to CGG repeat expansion leads to demethylation of the upstream promoter and gene re-activation. (vi) The tetracycline analog minocycline blocks excessive translation caused by loss of FMRP. (B) Strategies to prevent or reverse RBP aggregation. (i) RNase-H-dependent ASOs reducing the levels of ataxin 2 alleviate TDP-43 aggregation and toxicity. (ii) Modulation of chaperones such as heat shock proteins (hsp) and disaggregases such as nuclear import factors reverse abnormal phase transition and aggregation of RBPs. (C) Strategies to block RBP sequestration by repeat-expanded RNAs and proteins. ASOs have been applied to alleviate RBP sequestration by repeat expanded RNAs both by blocking and displacing muscleblind proteins or by degrading the toxic RNA in myotonic dystrophy (i), ASOs inducing isoform-specific degradation of expansion-containing transcripts alleviated pathology without reducing overall levels of C9ORF72 in ALS and/or FTD (ii). CRISPR technology was applied to repeat expansion diseases to either excise the repeat expansion or to block RNA Pol II transcription in the absence of nuclease activity (iii).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, Laferriere F, Maniecka Z, Plückthun A, Mittl P, et al. (2017). Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat. Commun 8, 45. - PMC - PubMed
    1. Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S, Sakakibara S, Miura M, Matsuo N, Darnell RB, and Okano H (1999). Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc. Natl. Acad. Sci. USA 96, 9885–9890. - PMC - PubMed
    1. Akten B, Kye MJ, Hao le T, Wertz MH, Singh S, Nie D, Huang J, Merianda TT, Twiss JL, Beattie CE, et al. (2011). Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc. Natl. Acad. Sci. USA 108, 10337–10342. - PMC - PubMed
    1. Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. (2014). Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81, 536–543. - PMC - PubMed
    1. Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S, and Tavazoie SF (2015). HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell 162, 1299–1308. - PMC - PubMed

Publication types

MeSH terms